BEAM-201

BEAM-201

Contact

 If you are interested in participating in the study or want to learn more, please contact: Contact us
This study is now recruiting. Learn more about enrolling here.

Description
The purpose of this study is to determine the safety and effectiveness of an experimental form of therapy, known as BEAM-201. BEAM-201 uses immune cells, called T cells, that are genetically changed to identify cancer cells. In this study, T cells are collected from a healthy human donor and have been modified in a laboratory. If the genetically changed T cells recognize and attach to cancer cells, they may have the ability to kill those cancer cells. The U.S. Food and Drug Administration (FDA) allows BEAM-201 to be used in research. Patients with T-cell Acute Lymphoblastic Leukemia (T-ALL) or T-cell Lymphoblastic Lymphoma (L-LL), where the disease has come back (relapsed) or has not responded to treatment (refractory) may be eligible for the study. 

Eligibility and criteria
IRB Number:
22-020678
Eligible age range:
1 months - 30 years
Clinical trial phase:
Phase I
Phase II
Official title:
A PHASE 1/2, DOSE-EXPLORATION AND DOSE-EXPANSION STUDY EVALUATING THE SAFETY AND EFFICACY OF MULTIPLEX BASE EDITED, ALLOGENEIC ANTI-CD7 CAR-T CELLS (BEAM-201) IN RELAPSED/REFRACTORY T-CELL ACUTE LYMPHOBLASTIC LEUKEMIA (T-ALL) OR T-CELL LYMPHOBLASTIC LYMPHOMA (T-LL)

What to expect
As a participant in the research, you will:
  • Receive the study drug BEAM-201.
  • Avoid taking certain medications (steroids, chemotherapy agents).
  • Stay in the hospital for at least 10 days after receiving the study drug.
  • Complete follow up visits.
  • Have research blood samples drawn.
Smiling CHOP patient holding shopping bag

We need families like you

Your time and participation make a difference in supporting the work of the Research Institute and children in our community. Learn more about opportunities to participate in our research.